Use of thalidomide in dermatological indications

BioDrugs

Volumn 13, Issue 4, 2000, Pages 255-265

  Kontogiannis, Vlassis ^a   Powell, Richard J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

APHTHOUS ULCER; BEHCET DISEASE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM LEPROSUM; GRAFT VERSUS HOST REACTION; HISTIOCYTOSIS X; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LUPUS ERYTHEMATOSUS; LYMPHOCYTIC INFILTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURIGO; PRURITUS; PYODERMA GANGRENOSUM; REVIEW; SARCOIDOSIS; SKIN DISEASE; T LYMPHOCYTE; TERATOGENICITY;

EID: 0034013146     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013040-00004     Document Type: Review

References (113)

1. 1. Barnhill R, Doll N, Millikan L, et al. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11 (5 Pt 1): 814-9
2. 2. Sampaiol E, Sarno E, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
3. 3. Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, et al. IgG antibody subclasses, tumor necrosis factor and IFN-γ levels in patients with type II lepra reaction on thalidomide treatment. Int Arch Allergy Immunol 1998; 116: 60-6
4. 4. Moreira A, Sampaio E, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80
5. 5. Neubert R, Nogueira A, Neubert D. Thalidomide derivatives and the immune system. I. Changes in the patterns of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993; 67: 1-17
6. 6. McHugh S, Rifkin I, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-7
7. 7. Haslett P, Corral L, Albert M, et al. Thalidomide costimulates primary human T-lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-92
8. 8. Klausner J, Freedman V, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81: 219-23
9. 9. D'Amato R, Loughnan M, Flynn E, et al. Thalidomide is inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5
10. 10. Lockwood D, Bryceson A. Leprosy. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 2. 6th ed. Oxford: Blackwell Science, 1998: 1215-35
11. 11. Kaplan G, Cohn ZA. Leprosy and cell mediated immunity. Curr Opin Immunol 1991; 3: 91-6
12. 12. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-11
13. 13. Iyer C, Languillon J, Ramanujam K, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971; 45: 719-32
14. 14. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide. Int J Dermatol 1980; 19: 318-22
15. 15. Koch H. Thalidomide and congeners as anti-inflammatory drugs. Prog Med Chem 1985; 22: 165-242
16. 16. Sampaio E, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-14
17. 17. Shannon E, Ejigu M, Haile-Mariam H, et al. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev 1992; 63: 5-11
18. 18. Rogers III R. Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders. Semin Cut Med Surg 1997; 16: 278-83
19. 19. Mascaro J, Lecha M, Torra H. Thalidomide in the treatment of recurrent necrotic and giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1979; 115: 636-7
20. 20. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985; 12: 85-90
21. 21. Revuz J, Guillaume JC, Janier M, et at. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990; 126: 923-7
22. 22. International study group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80
23. 23. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome [letter]. Arch Dermatol 1982; 118: 536
24. 24. Gardner-Medwin J, Smith N, Powell R. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828-32
25. 25. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. Ann Intern Med 1998; 128: 443-50
26. 26. Sontheimer R, Provost T. Lupus erythematosus. In: Sontheimer R, Provost T, editors. Cutaneous manifestations of rheumatic disease. Baltimore (MD): Williams and Wilkins, 1996: 1-71
27. 27. Naafs B, Bakkers E, Flinterman J, et al. Thalidomide treatment for subacute cutaneous lupus erythematosus. Br J Dermatol 1982; 107: 83-6
28. 28. Samsoen M, Grosshans E, Basset A. La thalidomide dans le traitement du lupus erythemateux chronique. Ann Dermatol Venereol 1980; 107: 515-23
29. 29. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983; 108: 461-6
30. 30. Hasper M. Chronic cutaneous lupus erythematosus: thalidomide treatment of 11 patients. Arch Dermatol 1983; 119: 812-5
31. 31. Stevens R, Andujar C, Edwards C, et al. Thalidomide in the treatment of cutaneous lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997; 36: 353-9
32. 32. Knop J, Happle R, Vakilzadech F, et al. Treatment of lupus erythematosus profundus with thalidomide. Arch Dermatol Res 1981; 270: 229
33. 33. Burrows N, Walport M, Hammond A, et al. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol 1991; 125: 62-7
34. 34. Georgala S, Katoulis A, Hasapi V, et al. Thalidomide treatment for hypertrophic lupus erythematosus [letter]. Clin Exp Dermatol 1998; 23: 141
35. 35. Burton J, Holden C. Nodular prurigo. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 1. 6th ed. Oxford: Blackwell Science, 1998: 671-2
36. 36. Vaalasti A, Suomalainen H, Rechardt L. Calcitonin gene-related peptide immunoreactivity in prurigo nodularis: a comparative study with neurodermatitis circumscripta. Br J Dermatol 1989; 120: 619-23
37. 37. Sheskin J. Zur therapie der prurigo nodularis hyde mit thalidomid. Hautarzt 1975; 26: 215-7
38. 38. Winkelmann R, Connolly S, Doyle J, et al. Thalidomide treatment for prurigo nodularis. Acta Derm Venereol 1984; 64: 412-7
39. 39. Johnke H, Zachariae H. Thalidomide treatment for prurigo nodularis. Ugeskr Laeger 1993; 155: 3028-30
40. 40. Ferrandiz C, Carrscossa J, Just M, et al. Sequential combined therapy with thalidomide and narrow-hand (TL01) UVB in the treatment of prurigo nodularis. Dermatology 1997; 195: 359-61
41. 41. Hawk J. Actinic prurigo. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 2. 6th ed. Oxford: Blackwell Science, 1998: 986-7
42. 42. Birt A, Davis R. Photodermatitis in North American Indians: familial actinic prurigo. Int J Dermatol 1971; 10: 107-14
43. 43. Londono F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973; 12: 326-8
44. 44. Saul A, Flores O, Navales J. Polymorphous light eruption: treatment with thalidomide. Austr J Dermatol 1976; 17: 17-21
45. 45. Lovell C, Hawk J, Calnan C, et al. Thalidomide in actinic prurigo. Br J Dermatol 1983; 108: 467-71
46. 46. Rowell N, Goodfield M. Graft-versus-host reactions. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/-Ebling textbook of dermatology. Vol. 3. 6th ed. Oxford: Blackwell Science, 1998: 2516-9
47. 47. Lim S, McWhannell A, Vora A, et al. Successful treatment with thalidomide of acute graft-versus-host disease after bonemarrow transplantation [letter]. Lancet 1988; 1: 117
48. 48. Vogelsang G, Farmer E, Hess A, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055-8
49. 49. Parker P, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604-9
50. 50. Youle M, Clarbour J, Farthing C, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody Br Med J 1989; 298: 432
51. 51. Paterson D, Georghiou P, Allworth A, et al. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995; 20: 250-4
52. 52. Jacobson J, Greenspan J, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336: 1487-93
53. 53. Hillman R, Goldmeier D, Taylor-Robinson D. Scrotal ulceration in HIV-positive patients. Genitourin Med 1990; 66: 93-4
54. 54. Verberkmoes A, Boer K, Wertheim P, et al. Thalidomide for genital ulcer in HIV-positive woman [letter]. Lancet 1996; 347: 974
55. 55. Georghiou P, Allworth A. Thalidomide in painful AIDS-associated proctitis. J Infect Dis 1992; 166: 939-40.
56. 56. Wallach F, Murray H. Thalidomide in painful AIDS associated proctitis [letter]. J Infect Dis 1992; 166: 939
57. 57. Sterling J, Kurtz J. Kaposi's sarcoma in AIDS. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 2. 6th ed. Oxford: Blackwell Science, 1998: 1063-4
58. 58. Soler R, Howard M, Brink N, et al. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996; 23: 501-3
59. 59. Fife K, Howard M, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998; 9: 751-5
60. 60. Matthews S, Cockerell C. Prurigo nodularis in HIV-infected individuals. Int J Dermatol 1998; 37: 401-9
61. 61. Herranz P, Pizarro A, De Lucas R, et al. Treatment of AIDS-associated prurigo nodularis with thalidomide. Clin Exp Dermatol 1998; 23: 233-5
62. 62. Berger T, Hoffman C, Thieberg M, et al. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol 1995; 33: 837-8
63. 63. MacKie R. Jessner's lymphocytic infiltrate. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 3. 6th ed. Oxford: Blackwell Science, 1998: 2400-1
64. 64. Moulin G, Bonnet F, Barrut D, et al. Treatment of Jessner-Kanof disease with thalidomide. Ann Dermatol Veneorol 1983; 110: 611-4
65. 65. Guillaume J, Moulin G, Dieng M, et al. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol 1995; 131: 1032-5
66. 66. Gawkrodger D. Sarcoidosis of the skin. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 3. 6th ed. Oxford: Blackwell Science, 1998: 2686-96
67. 67. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-9
68. 68. Rousseau L, Beylot-Barry M, Doutre M, et al. Cutaneous sarcoidosis successfully treated with low doses of thalidomide [letter]. Arch Dermatol 1998; 134: 1045-6
69. 69. Lee J, Koblenzer P. Disfiguring cutaneous, manifestation of sarcoidosis treated w ith thalidomide: a case report. J Am Acad Dermatol 1998; 39 5 Suppl. 2: 835-8
70. 70. Weisman K, Graham R. Renal disease. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 3. 6th ed. Oxford: Blackwell Science, 1998: 2728-31
71. 71. Silva S, Viana P, Lugon N, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994; 67: 270-3
72. 72. Dowd P, Champion R. Erythema multiforme. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 3. 6th ed. Oxford: Blackwell Science, 1998: 2081-5
73. 73. Moisson Y, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme [letter]. Br J Dermatol 1992; 126: 92-3
74. 74. Cherouati K, Claudy A, Souteyrand P, et al. Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients. Ann Dermatol Venereol 1996; 123: 375-7
75. 75. Wolkenstein P, Latarjet J, Roujeau C-J, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-9
76. 76. Chu A. Langerhans' cell histiocytosis. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 3. 6th ed. Oxford: Blackwell Science, 1998: 2315-23
77. 77. Gnassia A, Gnassia T, Bonvalet D, et al. Histiocytose X avec 'granulome éosinophile vulvaire': effect speculaire de la thalidomide. Ann Dermatol Venereol 1987; 114: 1387-9
78. 78. Misery L, Larbre B, Lyonnet S, et al. Remission of Langerhans cell histiocytosis with thalidomide treatment [letter]. Clin Exp Dermatol 1993; 18: 487
79. 79. Meunier L, Marck Y, Ribeyre C, et al. Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment [letter]. Br J Dermatol 1995; 132: 168
80. 80. Bensaid P, Machet L, Vaillant L, et al. Histiocytose Langerhansienne de l'adulte: localization parotidienne régressive aprés traitement par thalidomide. Ann Dermatol Venereol 1992; 119: 281-3
81. 81. Viraben R, Dupre A, Gorguet B. Pure cutaneous histiocytosis resembling sinus histiocytosis. Clin Exp Dermatol 1988; 13: 197-9
82. 82. Ryan T. Pyoderma gangrenosum. In: Champion R, Burton J, Burns D, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Vol. 3. 6th ed. Oxford: Blackwell Science, 1998: 2186-92
83. 83. Venencie P, Saurat J. Pyoderma gangrenosum chez un enfant. Traitement par la thalidomide. Ann Pediatr 1982; 29: 67-9
84. 84. Farrell A, Black M, Bracka A, et al. Pyoderma gangrenosum of the penis. Br J Dermatol 1998; 138: 337-40
85. 85. Hecker M, Lebwhol M. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 1998; 38: 490-1
86. 86. Rustin M, Gilkes J, Robinson T. Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. J Am Acad Dermatol 1990; 23: 941-4
87. 87. Munro C, Cox N. Pyoderma gangrenosum associated with Behçet's syndrome: response to thalidomide. Clin Exp Dermatol 1988; 13: 408-10
88. 88. Dereure O, Basset-Seguin N, Guilhou J. Erosive lichen planus: dramatic response to thalidomide [letter]. Arch Dermatol 1996; 132: 1392-3
89. 89. Perez Alfonso R, Weiss E, Piquero Martin J, et al. Generalized lichen planus with erosive lesions of the penis, treated with thalidomide: report of a case and review of the literature. Med Cutan Ibero Lat Am 1987; 15: 321-6
90. 90. Menendez-Ramos F, Razquin-Murillo J, Jimenez-Sanchez F, et al. Successful treatment of a case of erosive plantar lichen planus with thalidomide. Austr J Dermatol 1997; 38 Suppl. 2: 216-7
91. 91. Eravelly L, Walters M. Thalidomide in Weber-Christian disease [letter]. Lancet 1977; 1: 251
92. 92. Schnitzler L. Beneficial effect of thalidomide in a case of Hailey-Hailey pemphigus: I years' trial [letter]. Ann Dermatol Venereol 1984; 111: 285-6
93. 93. Naafs B, Faber W. Thalidomide therapy: an open trial. Int J Dermatol 1985; 24: 131-4
94. 94. Laugier P, Gilardi S. Chronic erythematous oedema of the upper face (Degos): Morbihan disease [in French]. Ann Dermatol Venereol 1981; 108: 507-63
95. 95. Randell T. Thalidomide back in the news, but in more favourable circumstances. JAMA 1990; 263: 1467-8
96. 96. Gollop T, Eigier A, Neto J. Prenatal diagnosis of thalidomide syndrome. Prenat Diagn 1987; 7: 295-8
97. 97. Stephens T. Proposed mechanisms of action in thalidomide emhryopathy. Teratology 1988; 38: 229-39
98. 98. Parman T, Wiley M, Wells P. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999; 5: 582-5
99. 99. Argilés J, Carbo N, Lopez-Soriano F. Was tumor necrosis factor-α responsible for the fetal malformations associated with thalidomide in the early 1960s? Med Hypotheses 1998; 50: 313-8
100. 100. Ochonisky S, Verroust J, Bastuji-Garin S, et al. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66-9
101. 101. Fullerton P, O'Sullivan D. Thalidomide neuropathy: a clinical, electrophysiological and histological follow-up study. J Neurol Neurosurg Psychiatry 1968; 31: 543-51
102. 102. Clemmensen O, Zander Olsen P, Andersen K.Thalidomide neurotoxicity. Arch Dermatol 1984; 120: 338-41
103. 103. Aronson I, Yu R, West D, et al. Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. Arch Dermatol 1984; 120: 1466-70
104. 104. Wulff C, Hoyer H, Asboe-Hansen G, et al. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475-80
105. 105. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf 1992; 7: 116-34
106. 106. Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996; 35: 969-79
107. 107. Rua-Figueroa I, Erausquin C, Naranjo A, et al. Pustuloderma during cutaneous lupus treatment with thalidomide. Lupus 1999; 8: 248-9
108. 108. Bielsa I, Teixido J, Ribera M, et al. Erythroderma due to thalidomide: report of two cases. Dermatology 1994; 189: 179-81
109. 109. Salafia A, Kharkar R. Thalidomide and exfoliative dermatitis [letter]. Int J Lepr Other Mycobact Dis 1988; 56: 625
110. 110. Ordi J, Cortes F, Martinez N, et al. Thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum 1998 Dec; 41 (12): 2273-5
111. 111. Gompel A, Frances C, Piette JC, et al. Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al. Arthritis Rheum 1999 Oct; 42 (10): 2259-60
112. 112. Powell RJ, Gardner-Medwin J. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994; 70: 901-4
113. 113. Lary JM, Lyon Daniel K, Erickson JD, et al. The return of thalidomide: can birth defects be prevented? Drug Saf 1999; 21 (3): 161-9